M Evans

Summary

Country: UK

Publications

  1. ncbi Linagliptin as add-on therapy for type 2 diabetes - an overview
    D X Brown
    University Hospital Llandough, Wales, UK
    Drugs Today (Barc) 48:645-54. 2012
  2. ncbi The myotoxicity of statins
    Marc Evans
    Department of Diabetes and Endocrinology, University Hospital of Wales, Heath Park, Cardiff, UK
    Curr Opin Lipidol 13:415-20. 2002
  3. ncbi A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations
    M Evans
    Department of Medicine, University Hospital of Wales, Cardiff, UK
    Diabetes Obes Metab 13:677-84. 2011
  4. ncbi The future direction of cholesterol-lowering therapy
    Marc Evans
    Department of Metabolic Medicine, University Hospital of Wales, Cardiff, UK
    Curr Opin Lipidol 13:663-9. 2002
  5. ncbi Medical lipid-regulating therapy: current evidence, ongoing trials and future developments
    Marc Evans
    Department of Metabolic Medicine, Diabetes and Endocrinology, University of Wales College of Medicine, Cardiff, Wales
    Drugs 64:1181-96. 2004
  6. ncbi Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus
    M Evans
    Cardiovascular Sciences Research Group, University Hospital of Wales, Cardiff, UK
    Circulation 101:1773-9. 2000
  7. ncbi A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes
    P McEwan
    Cardiff Research Consortium, Cardiff, UK
    Diabetes Obes Metab 12:623-30. 2010
  8. ncbi Management of diabetes in cardiovascular patients: diabetic heart disease
    R Peter
    Llandough Hospital, Llandough, Cardiff, UK
    Heart 94:369-75. 2008
  9. ncbi Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs
    C Ll Morgan
    Department of Epidemiology, Pharmatelligence, Cardiff, UK
    Diabetes Obes Metab 14:424-32. 2012
  10. ncbi Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus
    M Evans
    Cardiovascular Sciences Research Group, Department of Medicine, University Hospital of Wales, Cardiff, Heath Park, UK
    Eur J Clin Invest 33:231-8. 2003

Collaborators

Detail Information

Publications13

  1. ncbi Linagliptin as add-on therapy for type 2 diabetes - an overview
    D X Brown
    University Hospital Llandough, Wales, UK
    Drugs Today (Barc) 48:645-54. 2012
    ..It therefore represents a major advancement in the pharmacotherapy of patients with T2D...
  2. ncbi The myotoxicity of statins
    Marc Evans
    Department of Diabetes and Endocrinology, University Hospital of Wales, Heath Park, Cardiff, UK
    Curr Opin Lipidol 13:415-20. 2002
    ....
  3. ncbi A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations
    M Evans
    Department of Medicine, University Hospital of Wales, Cardiff, UK
    Diabetes Obes Metab 13:677-84. 2011
    ..Enhancing the pharmacological predictability and extending the duration of action could simplify insulin titration and further reduce the incidence of hypoglycaemia...
  4. ncbi The future direction of cholesterol-lowering therapy
    Marc Evans
    Department of Metabolic Medicine, University Hospital of Wales, Cardiff, UK
    Curr Opin Lipidol 13:663-9. 2002
    ....
  5. ncbi Medical lipid-regulating therapy: current evidence, ongoing trials and future developments
    Marc Evans
    Department of Metabolic Medicine, Diabetes and Endocrinology, University of Wales College of Medicine, Cardiff, Wales
    Drugs 64:1181-96. 2004
    ..In addition, the pleiotropic anti-inflammatory effects of lipid lowering therapy may provide further risk reduction...
  6. ncbi Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus
    M Evans
    Cardiovascular Sciences Research Group, University Hospital of Wales, Cardiff, UK
    Circulation 101:1773-9. 2000
    ..Exaggerated postprandial lipemia (PPL) is a factor in atherogenesis, involving endothelial dysfunction and enhanced oxidative stress. We examined the effect of ciprofibrate therapy on these parameters in type 2 diabetes mellitus...
  7. ncbi A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes
    P McEwan
    Cardiff Research Consortium, Cardiff, UK
    Diabetes Obes Metab 12:623-30. 2010
    ....
  8. ncbi Management of diabetes in cardiovascular patients: diabetic heart disease
    R Peter
    Llandough Hospital, Llandough, Cardiff, UK
    Heart 94:369-75. 2008
  9. ncbi Weight change in people with type 2 diabetes: secular trends and the impact of alternative antihyperglycaemic drugs
    C Ll Morgan
    Department of Epidemiology, Pharmatelligence, Cardiff, UK
    Diabetes Obes Metab 14:424-32. 2012
    ..This study aimed to describe the pattern of weight change in people with type 2 diabetes (T2DM) over time and when using alternative treatment regimens...
  10. ncbi Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus
    M Evans
    Cardiovascular Sciences Research Group, Department of Medicine, University Hospital of Wales, Cardiff, Heath Park, UK
    Eur J Clin Invest 33:231-8. 2003
    ..2 Iu kg-1) and vitamin C 1-g daily. Eight-h lipid and glucose profiles were measured following a fatty meal. Endothelial function (flow-mediated vasodilatation: FMD) and OS were measured at fasting, 4 h and 8 h...
  11. ncbi Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model
    P McEwan
    Cardiff Research Consortium, Cardiff, Wales, UK
    Diabetes Obes Metab 12:431-6. 2010
    ..We therefore sought to ascertain the respective contribution of hypoglycaemia, weight change and improved blood glucose control on second-line therapy options added to metformin...
  12. ncbi Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008
    C J Currie
    Department of Medicine, School of Medicine, Cardiff University, The Pharma Research Centre, Cardiff Medicentre, Cardiff, Wales, UK
    Diabet Med 27:744-52. 2010
    ..A variety of influences determine prescribing behaviour. The purpose of this study was to characterize the pattern of dispensing for glucose-lowering and monitoring in the UK from 2000 to 2008, inclusively...
  13. ncbi The influence of the Pro12Ala mutation of the PPAR-gamma receptor gene on metabolic and clinical characteristics in treatment-naïve patients with type 2 diabetes
    M Ahluwalia
    School of Applied Sciences, University of Wales Institute Cardiff, Cardiff, UK
    Diabetes Obes Metab 4:376-8. 2002
    ..The P12A allele associated with lower fasting plasma glucose but had no influence on HbA1c or BMI. In obese patients (BMI > 29 kg/m2), the P12A substitution associated with elevated total and non-HDL cholesterol levels...